Free Trial

Zacks Research Forecasts Exelixis' Q3 Earnings (NASDAQ:EXEL)

Exelixis logo with Medical background

Key Points

  • Zacks Research has raised its Q3 2025 EPS estimate for Exelixis to $0.57, indicating positive growth from the previous estimate of $0.55, and full-year earnings are estimated at $2.04 per share.
  • Exelixis shares have received mixed reactions from various brokerages, with price targets ranging from $40.00 to $50.00, reflecting a consensus rating of "Moderate Buy" from analysts.
  • The biotechnology company's recent earnings report showed a net margin of 27.01% but a decline in revenue of 10.8% compared to the same quarter last year, with an EPS of $0.75 beating estimates.
  • Want stock alerts on Exelixis? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for Exelixis in a research report issued to clients and investors on Monday, August 18th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $0.57 for the quarter, up from their previous forecast of $0.55. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' FY2025 earnings at $2.32 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.Exelixis's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period last year, the company earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS.

Several other research firms have also commented on EXEL. Barclays raised their target price on Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a report on Thursday, July 10th. JMP Securities reaffirmed a "market outperform" rating and set a $50.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. Wall Street Zen lowered Exelixis from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, William Blair reissued an "outperform" rating on shares of Exelixis in a report on Tuesday, July 29th. Thirteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $44.06.

Check Out Our Latest Research Report on EXEL

Exelixis Stock Performance

Exelixis stock traded down $0.08 during midday trading on Wednesday, hitting $38.63. 1,509,932 shares of the company were exchanged, compared to its average volume of 3,944,861. The firm has a market capitalization of $10.40 billion, a PE ratio of 18.57, a price-to-earnings-growth ratio of 0.80 and a beta of 0.29. Exelixis has a fifty-two week low of $25.12 and a fifty-two week high of $49.62. The business has a fifty day simple moving average of $41.56 and a two-hundred day simple moving average of $39.32.

Insider Activity at Exelixis

In related news, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the transaction, the director owned 358,882 shares in the company, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Sue Gail Eckhardt sold 18,838 shares of Exelixis stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total value of $805,136.12. Following the completion of the sale, the director owned 21,380 shares in the company, valued at $913,781.20. This represents a 46.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.82% of the company's stock.

Institutional Investors Weigh In On Exelixis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC grew its stake in Exelixis by 8.9% during the 4th quarter. Barclays PLC now owns 348,009 shares of the biotechnology company's stock worth $11,587,000 after purchasing an additional 28,420 shares in the last quarter. Mariner LLC grew its stake in Exelixis by 13.1% during the 4th quarter. Mariner LLC now owns 20,373 shares of the biotechnology company's stock worth $678,000 after purchasing an additional 2,355 shares in the last quarter. United Capital Financial Advisors LLC acquired a new position in Exelixis during the 4th quarter worth $207,000. NewEdge Advisors LLC grew its stake in Exelixis by 113.8% during the 4th quarter. NewEdge Advisors LLC now owns 27,908 shares of the biotechnology company's stock worth $929,000 after purchasing an additional 14,857 shares in the last quarter. Finally, Forum Financial Management LP acquired a new position in Exelixis during the 4th quarter worth $241,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

About Exelixis

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Read More

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Should You Invest $1,000 in Exelixis Right Now?

Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines